26 results about "Anticoagulant Agent" patented technology

The invention belongs to the technical field of biomedical materials, and particularly relates to a poly-4-methyl-1-pentene (PMP) gas-blood exchange membrane for an extracorporeal membrane oxygenation (ECMO) system, which realizes a long-acting antithrombotic function through a bionic interface construction technology. The invention aims to provide a bionic antithrombotic PMP gas-blood exchange membrane based on zwitter-ion gradient grafting, and through material and process innovation, the following problems existing in a traditional ECMO gas-blood exchange membrane: an antithrombotic coating is easy to fall off, and the long-term effect is insufficient; the risk of blood injury caused by dependence on heparin or anticoagulants; and the surface modification process destroys the membrane pore structure and air permeability.

The utility model discloses a blood filtering treatment device, which relates to the technical field of filtering equipment and comprises a shell, and a liquid outlet notch communicated with an inner cavity of the shell is formed in the bottom wall of the shell; the filter cartridge is fixedly arranged in the cavity of the shell, and a plurality of filtrate ports are formed in the outer wall of the lower part of the filter cartridge in a penetrating manner; the hopper is arranged on the outer wall above the shell, and the lower end of the hopper is communicated with the inner wall of the filter drum. According to the blood filtering treatment device, blood and impurities are separated at a time, meanwhile, the shape of the impurities is not damaged, the product quality is not affected, blood clots coagulated in the blood can be reduced to be in a liquid state through equipment, the cost of an anticoagulant agent is saved from the source, the additional value of the product is greatly improved, and the production cost is reduced. According to the innovation of the equipment, the use area of a filtering workshop is greatly saved, the capital investment is reduced, and the equipment realizes breakthrough innovation in the blood filtering field, integrates independent crushing and independent filtering forms, and realizes the effect of integrating hair removal and pulping.

The invention relates to the technical field of liquid-based cytology, and particularly discloses serosa effusion cell preserving fluid. Comprising a preservation solution, an anticoagulant, a red blood cell treatment solution, a cell membrane stabilizer, an antioxidant and a metal ion chelating agent, the preservation solution contains a buffer system, an energy supply component, an antibiotic and a surfactant, and the red blood cell treatment solution contains a hemolysis active component and a cell immobilization component; the preparation method comprises the following steps: firstly, preparing the preserving fluid, adjusting the pH value, adding the active substances, mixing the antibiotics, and then completing constant volume and sterile filtration; the anticoagulant solution and the red blood cell treating fluid are independently prepared, and sterilization is achieved through filtration; and finally, packaging all the components in a sterilized storage bottle in a matched manner. The composition provided by the invention can be used for preserving cells in a clinical serosal effusion sample, and can provide a high-quality sample for subsequent cell morphology observation or detection; in addition, according to the preparation method, the controllability is high when all the components are independently prepared, and the preserving fluid with the consistent performance can be stably prepared.

This invention discloses a method and application for fetal red blood cell flow cytometry detection, comprising the following steps: taking fetal blood and placing it in a test tube; adding the test tube containing fetal blood to an anticoagulant tube; adding an anticoagulant to the blood in the anticoagulant tube; placing the anticoagulant tube containing blood and anticoagulant into a blood centrifuge; centrifuging the fetal blood in the anticoagulant tube; after centrifugation, the fetal blood in the anticoagulant tube separates into layers; recording the proportion of each layer; red blood cells are generally in the lowest layer. This invention has the advantage of being able to detect the number of hemoglobin cells in red blood cells, solving the problem that current methods for detecting fetal red blood cells generally only detect the number of fetal red blood cells, and only determine the health of the fetus by the number of fetal red blood cells. The inability to detect the number of hemoglobin cells in fetal red blood cells reduces the accuracy of the detection and is not conducive to understanding the health status of the fetus.

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The application discloses a kind of whole-process intelligent quality control and traceability system and method of test specimen, it is related to specimen testing technical field, the application first records the collection information of specimen, then according to the collection information of specimen analysis obtains the configuration information of specimen anticoagulant, and then according to the configuration information corresponding anticoagulant is configured and is added specimen, to obtain the test information of specimen, after testing is completed, the traceability reference value of specimen is analyzed, and the traceability correlation chain is constructed, then determine traceability data, and traceability data is distributed to each traceability node, finally each traceability data and traceability node are stored.The application realizes the individualization intelligent adaptation of anticoagulant proportioning, effectively avoids the test result deviation problem caused by traditional fixed anticoagulant proportioning, simultaneously solves the problem that existing traceability data is scattered and correlation is poor, improves the credibility of traceability data.

A medical device may be coated with a therapeutic composition comprising a direct oral anticoagulant. An exemplary drug coating composition may include an excipient including polylactic acid (PLA), poly (lactic acid-co-glycolic acid) (PLGA), or poly (vinylidene fluoride-co-hexafluoropropylene (PVDF-HFP), and a direct oral anticoagulant (DOAC). An exemplary pharmaceutical coating may be applied to an exterior surface of a medical device.

This invention relates to the field of biomedicine, specifically to the application of banana fruit extract in the preparation of anticoagulant or antithrombotic drugs. The banana fruit extract provided by this invention contains flavonoids, polyphenols, polysaccharides, hydroxyanthraquinones, triterpenoids, and other components. Flavonoids and polyphenols have been widely proven to have anti-inflammatory and antioxidant effects, which can synergistically enhance the anticoagulant effect. The high potassium content of banana fruit can indirectly improve vascular function by regulating sodium-potassium balance. The banana fruit extract provided by this invention can inhibit platelet production or promote platelet metabolism, prolong clotting time, and inhibit platelet aggregation. Its natural plant components interfere with platelet aggregation by inhibiting the production of thromboxane A2, achieving anticoagulant and antithrombotic effects. The mechanism of action of banana fruit extract differs from traditional anticoagulants such as heparin, reducing the risk of bleeding. Its natural component characteristics provide a direction for the development of novel plant-derived anticoagulant drugs.

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

Current approaches in small diameter vascular grafts for coronary artery bypass surgeries fail to address physiological variations along the graft that contribute to thrombus formation and ultimately graft failure. An interlayer drug delivery system can sustain delivery of heparin through the graft with a high degree of temporal and spatial control. A heparin-loaded gelatin methacrylate interlayer sits between a biohybrid composed of decellularized bovine pericardium and poly(propylene fumarate) and UV crosslinking is controlled via 3D printed shadow masks. The masks enable control of the resultant gelMA crosslinking and properties by modulating the incident light intensity on the graft. High doses of heparin have detrimental effects on endothelial cell function. When exposed to heparin in a slower, more sustained manner consistent with the masks, endothelial cells behave similarly to untreated cells. Slower release profiles cause significantly more release of tissue factor pathway inhibitor, an anticoagulant, than a faster release profile.

The application discloses a kind of automatic penetration sampling machines for nursing in nephrology department, and relates to the technical field of sampling device.It includes base, the upper surface of base is slidably connected with fixing frame, a plurality of groups of placing grooves are formed in the upper surface of fixing frame, and test tubes are arranged on the inner wall of placing groove, a plurality of groups of positioning cylinders are movably arranged on the upper surface of fixing frame, a transmission assembly for moving fixing frame is arranged in the base, a lifting assembly is arranged at the right position on the upper surface of base, and the lifting assembly includes motor.The application realizes automatic mixing operation of sample and anticoagulant in test tube by mixing assembly, without manual operation, which reduces the insufficient mixing of sample caused by insufficient number of test tube inversion or insufficient inversion angle to a certain extent, and the test tube generates synchronous rotation during inversion, which greatly increases the contact area of sample and anticoagulant, improves the mixing effect, and improves the accuracy of subsequent detection results to a certain extent.

This application discloses a microfluidic detection chip and detection device for simultaneous multiple detections. The detection device includes a microfluidic detection chip for simultaneous multiple detections. The microfluidic chip includes a substrate, on which are formed a sample inlet chamber, at least two independent quantitative regions, and at least two independent detection regions, with each quantitative region corresponding to a detection region. The inlet of each quantitative region is connected to the sample inlet chamber, and the outlet of each quantitative region is connected to the detection region. An anticoagulant is placed within each quantitative region, and the anticoagulant used in different quantitative regions is different. The microfluidic detection chip and detection device disclosed in this application solve the problem of low detection efficiency in existing microfluidic detection chips.

Example compositions comprise Factor Xa, a substrate, one or more guanidine derivatives, and, in some cases, heparin. An example method for detecting an anticoagulant in a sample includes combining or contacting the sample with a composition and measuring the activity of factor Xa based on the status of the substrate. The composition modulates the activity of Factor Xa in a sample, wherein the modulation comprises reducing the rate of clotting in the sample caused by Factor Xa. The presence of an anticoagulant is based on the activity of factor Xa.

An example composition includes factor Xa, a substrate, one or more of guanidine derivatives, and, in some cases, heparin. An example method for detecting an anticoagulant in a sample includes combining or contacting the sample with the composition and measuring activity of the factor Xa based on a state of the substrate. The composition modulates the activity of the factor Xa in the sample, where modulation includes reducing a rate of coagulation of the sample caused by factor Xa. A presence of the anticoagulant is based on the activity of the factor Xa.

The present invention provides a method for using an anticoagulant reversal agent to prevent, treat or alleviate bleeding caused by anticoagulants. The anticoagulant reversal agent has a structure represented by formula I, can well inhibit bleeding complications caused by the anticoagulants, for example, can inhibit bleeding complications caused by the anticoagulants such as direct thrombin inhibitors and Xa factor inhibitors, and has the broad-spectrum and high-efficiency characteristics.

The application provides a high blood pressure blood sample protective agent, a vacuum blood collection tube for high blood pressure blood sample detection and application, and belongs to the technical field of medical devices. The high blood pressure blood sample protective agent is characterized in that raw materials of the high blood pressure blood sample protective agent include enalapril maleate, an anticoagulant and a complexing agent in terms of weight parts. The vacuum blood collection tube for high blood pressure blood sample detection has the high blood pressure blood sample protective agent. The application is to directly save blood by using the vacuum blood collection tube for high blood pressure blood sample detection. The vacuum blood collection tube for high blood pressure blood sample detection can reduce the cumbersome steps of reagent preparation and on-site reagent addition, thereby improving the detection efficiency and the accuracy of the detection result.

Provided is a blood collection container capable of inhibiting the mixing of leukocytes into plasma. The blood collection container of the present invention is a blood collection container for collecting a given amount of blood, wherein the blood collection container is provided with a blood collection container main body, a plasma separation material housed in the blood collection container main body, an osmotic pressure adjusting agent, and an anticoagulant, the specific gravity of the plasma separation material at 25°C is 1.030 or more and 1.120 or less, and in a case where the osmotic pressure adjusting agent and the anticoagulant housed in the blood collection container main body are dissolved with an amount of physiological saline equivalent to the given amount of blood collected in the blood collection container to obtain an osmotic pressure measurement solution, the specific gravity of the plasma separation material at 25°C and the osmotic pressure of the osmotic pressure measurement solution satisfy a specific relationship.

The utility model relates to the technical field of hemodialysis instruments, in particular to an integrated forward pre-flushing hemodialysis pipeline which comprises a three-way connector, and three connectors of the three-way connector are a hemodialysis machine connector directly connected with a hemodialysis machine, a hemodialysis pipe connector connected with an artery end hemodialysis pipeline and a pre-flushing end connector communicated with a pre-flushing pipeline. The pre-flushing pipeline and the artery pre-flushing pipeline are directly connected to the blood inlet end of the dialysis machine through the three-way connector, and the problems that during pre-flushing before dialysis, the number of operation steps is increased, and the risk that a person pollutes a link opening is caused are solved; and when blood is returned after dialysis, the problems that blood is returned at the front end of the artery under natural pressure during blood return, the blood can exceed the access end of the pre-flushing pipeline, the blood cannot enter when the internal fistula pressure is high, and blood coagulation possibly occurs when the pump is stopped to return the arterial blood when no anticoagulant or less anticoagulant exists are directly avoided.

The invention belongs to the technical field of medical treatment, and discloses a method and a system for separating self red blood cells. Comprising the following steps: washing red blood cells with normal saline for three times, removing supernatant as much as possible under the condition of retaining an albuginea layer, retaining packed red blood cells, and uniformly mixing; adding at least two tubes of uniformly mixed packed red cells into the capillary tube by using a sample adding gun; sealing the bottom of the pipe with sealing mud; putting the capillary tube with the sealing mud at one end downwards into a blood collection tube without an anticoagulant, and tightening a blood collection tube cap; centrifuging for 5 minutes by using a blood sample centrifugal machine, wherein the centrifugal force setting condition is 2000g or 3500rpm; after centrifugation, the sample is carefully and vertically taken out from the blood collection tube without shaking; cutting off a capillary tube at one end without sealing mud, namely a proximal end, and transferring cells 5 mm away from the upper part of the capillary tube into a 12 * 75 mm test tube; after washing with normal saline, centrifuging, introducing the intercepted 5mm capillary tube and washing liquid into a waste liquid cylinder, and retaining the volume of red blood cells. According to the method, the operation cost and the equipment investment are effectively reduced by reducing the equipment requirement and shortening the centrifugal time.

The invention provides a uniform mixing device and a sample analyzer, the uniform mixing device comprises: a uniform mixing unit for carrying a sample container, the sample container forming an accommodating cavity, the uniform mixing unit being used for uniformly mixing a to-be-mixed sample in the accommodating cavity; the control unit is electrically connected with the uniform mixing unit, and the control unit is used for acquiring the bottom position of the accommodating cavity and selecting the uniform mixing mode matched with the bottom position of the accommodating cavity, so that the uniform mixing unit performs uniform mixing operation on the to-be-uniformly-mixed sample in the accommodating cavity according to the matched uniform mixing mode. The mixing operation can be carried out by using one mixing unit in a mixing mode matched with the bottom position of the accommodating cavity, other structures do not need to be additionally arranged, and the situation that a detection result has large deviation due to the fact that the sample is not fully mixed and the wall hanging phenomenon of the sample is serious can be avoided, so that the detection accuracy is improved. Meanwhile, the contact between the sample to be uniformly mixed and the anticoagulant can be reduced, so that the detection result is more accurate.

The utility model discloses a multi-anticoagulant blood collection tube for inspection, which comprises a tube body, the tube body consists of a cap, an outer sleeve and an inner sleeve, the outer sleeve and the inner sleeve are concentric, and the cap is connected with the outer sleeve through threads. A plurality of sealed pipe cavities are designed in the inner sleeve, and the pipe cavities are separated through partition plates and filled with the same or different anticoagulants. And the top of the outer sleeve is sealed by a rubber plug and is provided with one or more puncture points. The inner sleeve is nested from the bottom to the top of the outer sleeve, the bottom is closed, a top opening is located below the rubber plug, and the space, located below the rubber plug, of the inner sleeve and the outer sleeve is in a vacuum state. The inner sleeve is rotated by adjusting the threads, so that openings of different tube cavities can be aligned with puncture points. A classification label is arranged at the bottom of the inner sleeve and is used for labeling corresponding tube cavities or anticoagulants such as heparin and EDTA-K2 salt. By means of the design, the blood sampling efficiency and the sample quality are improved, and the operation complexity in the blood sampling process is reduced.

This invention provides a natural rubber anticoagulant and latex-expelling accelerator and its application. The accelerator includes an anticoagulant, a cut repair agent, and an active stabilizer. The anticoagulant is a citrate, heparin ammonium salt, or dithiothreon derivative; the cut repair agent is a phenylurea derivative; and the active stabilizer is at least one of sorbitol, phenacetin, polyvinylpyrrolidone, and sodium octaborate tetrahydrate. The accelerator of this invention is safer and more efficient when applied to rubber tree tapping, promoting latex excretion and tree recovery, effectively saving bark consumption, significantly reducing ethylene stimulation concentration, effectively reducing the side effects of ethylene, obtaining ideal yield, accelerating the repair of cut bark, and reducing the risk of pathogen infection of wounds.

The application discloses a self-derived protein anticoagulant coating and a preparation method and application thereof. The coating utilizes the oxidation of hydrogen peroxide generated by the reaction of an oxidizing agent or a reducing agent with oxygen in the air, is based on the endogenous active center (such as hematin) removal mechanism of self-extracted proteins (such as hemoglobin), induces the oxidative self-assembly of the proteins, and loads an anticoagulant in the assembly process to form a protein-anticoagulant composite nanofilm. The application utilizes the self-proteins to avoid the transmission risk of pathogens such as HIV, PERVs and prions from the source; the preparation method is simple and rapid, and the obtained coating has excellent adhesion stability, good biocompatibility and anti-biofouling capacity on the surface of various substrates. In-vitro and in-vivo experiments prove that the coating has superior anticoagulant performance, reduces the risk of bleeding and liver and kidney toxicity, and can be used for the surface modification of blood-contacting medical devices such as a heart stent, an artificial blood vessel, a central venous catheter and an extracorporeal oxygenator.

A microfluidic, chip-based assay device has been developed for measuring the physical properties of an analyte (specifically, whole blood or whole blood derivatives). The technologies can be applied to measure the clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, and evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulant drugs and / or their reversal agents.The assay is anticoagulant-independent - clotting is initiated by exposing the blood sample within the device to a glass surface (or other negatively charged material such as oxidized silica), which activates the intrinsic pathway and can be further accelerated by applying shear flow across the surface of the activating materials. The absence of chemical activating agents and a highly controlled and reproducible microenvironment yield a universal point-of-care clotting assay.

This invention relates to the field of blood collection technology, and more particularly to a blood collection device for medical testing. It includes a blood collection tube pretreatment module, a tourniquet binding module for applying pressure to the patient's vein, and a vein identification and positioning module for identifying and locating the patient's veins, all positioned above a platform. The platform also houses a rotating disinfection module for contact with the patient's arm. The tourniquet is tightened via a tourniquet release mechanism, and a pressure sensor detects the pressure applied to the patient's arm, enabling automatic adjustment without manual binding, preventing over-tightening or under-tightening and ensuring binding quality. The vein identification and positioning module identifies the location of veins under the skin of the arm and uses infrared positioning for precise needle insertion by medical personnel, ensuring efficient and high-quality blood collection. After blood collection, the blood collection tube pretreatment module automatically shakes the vacuum collection tube to ensure the anticoagulant mixes with the blood sample, guaranteeing sample quality.

The invention discloses a blood glucose protection microsphere, a preparation method thereof and application of the blood glucose protection microsphere in a vacuum blood collection tube, and belongs to the technical field of medical instruments. The blood glucose protection microsphere is prepared by the following steps: preparing a solution from an anticoagulant, an anti-glycolysis agent, an excipient and a protective agent in proportion, freezing the solution through liquid nitrogen drop beads to form a microsphere precursor, and performing vacuum freeze drying to prepare a freeze-dried microsphere with the diameter of 2.0-6.0 mm. According to the preparation method, various functional reagents are integrated into the microspheres at one time, the process is simple, and energy conservation and consumption reduction are achieved. The microspheres can be quickly dissolved and uniformly dispersed when being applied to the vacuum blood collection tube, glycolysis is effectively inhibited, hemolysis is prevented, the accuracy and reliability of blood glucose detection are improved, and meanwhile, product quality control is facilitated.